|
1
|
The Editorial Board of the Cancer
Statistics in Japan, . Cancer statistics in Japan 2018. Foundation
for Promotion of Cancer Research; Tokyo: pp. 152019
|
|
2
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Murakami T, Hiroshima Y, Matsuyama R,
Homma Y, Hoffman RM and Endo I: Role of the tumor microenvironment
in pancreatic cancer. Ann Gastroenterol Surg. 3:130–137. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Oettle H, Neuhaus P, Hochhaus A, Hartmann
JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J,
Arning MB, et al: Adjuvant chemotherapy with gemcitabine and
long-term outcomes among patients with resected pancreatic cancer:
The CONKO-001 randomized trial. JAMA. 310:1473–1481. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Torphy RJ, Zhu Y and Schulick RD:
Immunotherapy for pancreatic cancer: Barriers and breakthroughs.
Ann Gastroenterol Surg. 2:274–281. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clevers H: The cancer stem cell: Premises,
promises, and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Lewis MT, Huang J, Gutierrez C,
Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC,
et al: Intrinsic resistance of tumorigenic breast cancer cells to
chemotherapy. J Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou BB, Zhang H, Damelin M, Geles KG,
Grindley JC and Dirks PB: Tumour-initiating cells: Challenges and
opportunities for anticancer drug discovery. Nat Rev Drug Discov.
8:806–823. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsunedomi R, Yoshimura K, Suzuki N, Hazama
S and Nagano H: Clinical implications of cancer stem cells in
digestive cancers: Acquisition of stemness and prognostic impact.
Surg Today. Feb 5–2020.(Epub ahead of print). doi:
10.1007/s00595-020-01968-x. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rasheed ZA, Yang J, Wang Q, Kowalski J,
Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, et
al: Prognostic significance of tumorigenic cells with mesenchymal
features in pancreatic adenocarcinoma. J Natl Cancer Inst.
102:340–351. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sureban SM, May R, Qu D, Weygant N,
Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG
and Houchen CW: DCLK1 regulates pluripotency and angiogenic factors
via microRNA-dependent mechanisms in pancreatic cancer. PLoS One.
8:e739402013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li C, Wu JJ, Hynes M, Dosch J, Sarkar B,
Welling TH, Pasca di Magliano M and Simeone DM: c-Met is a marker
of pancreatic cancer stem cells and therapeutic target.
Gastroenterology. 141:2218–2227. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ishimoto T, Nagano O, Yae T, Tamada M,
Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al:
CD44 variant regulates redox status in cancer cells by stabilizing
the xCT subunit of system xc (−) and thereby promotes tumor growth.
Cancer Cell. 19:387–400. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Watanabe Y, Yoshimura K, Yoshikawa K,
Tsunedomi R, Shindo Y, Matsukuma S, Maeda N, Kanekiyo S, Suzuki N,
Kuramasu A, et al: A stem cell medium containing neural stimulating
factor induces a pancreatic cancer stem-like cell-enriched
population. Int J Oncol. 45:1857–1866. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rawlings ND, Barrett AJ and Bateman A:
MEROPS: The database of proteolytic enzymes, their substrates and
inhibitors. Nucleic Acids Res. 40:D343–D350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Turk V, Stoka V, Vasiljeva O, Renko M, Sun
T, Turk B and Turk D: Cysteine cathepsins: From structure, function
and regulation to new frontiers. Biochim Biophys Acta. 1824:68–88.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kirschke H, Barrett AJ and Rawlings ND:
Proteinases 1: Lysosomal cysteine proteinases. Protein Profile.
2:1581–1643. 1995.PubMed/NCBI
|
|
20
|
Mort JS and Buttle DJ: Cathepsin B. Int J
Biochem Cell Biol. 29:715–720. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aggarwal N and Sloane BF: Cathepsin B:
Multiple roles in cancer. Proteomics Clin Appl. 8:427–437. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yan S, Berquin IM, Troen BR and Sloane BF:
Transcription of human cathepsin B is mediated by Sp1 and Ets
family factors in glioma. DNA Cell Biol. 79:79–91. 2000. View Article : Google Scholar
|
|
23
|
Li L and Davie JR: The role of Sp1 and Sp3
in normal and cancer cell biology. Ann Anat. 192:275–283. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dittmer J: The biology of the Ets1
proto-oncogene. Mol Cancer. 2:292003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Buggy Y, Maguire TM, McGreal G, McDermott
E, Hill ADK, O'Higgins N and Duffy MJ: Overexpression of the Ets-1
transcription factor in human breast cancer. Br J Cancer.
91:1308–1315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Japan Pancreas Society: General rules for
the study of pancreatic cancer, The 6th Edition, Revised Version
edn. Tokyo, Japan: Kanehara; pp. 3–14. 2013
|
|
27
|
Union for International Cancer Control
(UICC): TNM Classification of Malignant Tumours, 7th edition. Sobin
LH, Gospodarowicz MK and Wittekind C: Wiley; New York, NY: 2010
|
|
28
|
Yamamoto K, Yahara N, Gondo T, Ishihara T
and Oka M: Establishment and characterization of a new human
pancreatic cancer cell line, YPK-1. Bull Yamaguchi Med Sch.
49:33–42. 2002.
|
|
29
|
Gerashchenko BI, Yamagata A, Oofusa K,
Yoshizato K, de Toledo SM and Howell RW: Proteome analysis of
proliferative response of bystander cells adjacent to cells exposed
to ionizing radiation. Proteomics. 7:2000–2008. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matsukuma S, Yoshimura K, Ueno T, Oga A,
Inoue M, Watanabe Y, Kuramasu A, Fuse M, Tsunedomi R, Nagaoka S, et
al: Calreticulin is highly expressed in pancreatic cancer stem-like
cells. Cancer Sci. 107:1599–1609. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fujiwara N, Usui T, Ohama T and Sato K:
Regulation of beclin 1 protein phosphorylation and autophagy by
protein phosphatase 2A (PP2A) and death-associated protein kinase 3
(DAPK3). J Biol Chem. 291:10858–10866. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Enjoji S, Yabe R, Tsuji S, Yoshimura K,
Kawasaki H, Sakurai M, Sakai Y, Takenouchi H, Yoshino S, Hazama S,
et al: Stemness is enhanced in gastric cancer by a SET/PP2A/E2F1
axis. Mol Cancer Res. 16:554–563. 2008. View Article : Google Scholar
|
|
33
|
Yabe R, Tsuji S, Mochida S, Ikehara T,
Usui T, Ohama T and Sato K: A stable association with PME-1 may be
dispensable for PP2A demethylation-implications for the detection
of PP2A methylation and immunoprecipitation. FEBS Open Bio.
8:1486–1496. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ebert MP, Krüger S, Fogeron ML, Lamer S,
Chen J, Pross M, Schulz HU, Lage H, Heim S, Roessner A, et al:
Overexpression of cathepsin B in gastric cancer identified by
proteome analysis. Proteomics. 5:1693–1704. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
McKerrow JH, Bhargava V, Hansell E, Huling
S, Kuwahara T, Matley M, Coussens L and Warren R: A functional
proteomics screen of proteases in colorectal carcinoma. Mol Med.
6:450–460. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Srisomsap C, Subhasitanont P, Otto A,
Mueller EC, Punyarit P, Wittmann-Liebold B and Svasti J: Detection
of cathepsin B up-regulation in neoplastic thyroid tissues by
proteomic analysis. Proteomics. 2:706–712. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean
K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, et al:
Proteomics of human breast ductal carcinoma in situ. Cancer Res.
62:6740–6749. 2002.PubMed/NCBI
|
|
38
|
Mijanović O, Branković A, Panin AN,
Savchuk S, Timashev P, Ulasov I and Lesniak MS: Cathepsin B: A
sellsword of cancer progression. Cancer Lett. 449:207–214. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tang KD, Liu J, Jovanovic L, An J, Hill
MM, Vela I, Lee TK, Ma S, Nelson C, Russell PJ, et al: Adipocytes
promote prostate cancer stem cell self-renewal through
amplification of the cholecystokinin autocrine loop. Oncotarget.
7:4939–4948. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Niedergethmann M, Wostbrock B, Sturm JW,
Willeke F, Post S and Hildenbrand R: Prognostic impact of cysteine
proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma.
Pancreas. 29:204–211. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Komura T, Takabatake H, Harada K, Yamato
M, Miyazawa M, Yoshida K, Honda M, Wada T, Kitagawa H, Ohta T, et
al: Clinical features of cystatin A expression in patients with
pancreatic ductal adenocarcinoma. Cancer Sci. 108:2122–2129. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Krueger S, Haeckel C, Buehling F and
Roessner A: Inhibitory effects of antisense cathepsin B cDNA
transfection on invasion and motility in a human osteosarcoma cell
line. Cancer Res. 59:6010–6014. 1999.PubMed/NCBI
|
|
43
|
Shimizu A, Nakayama H, Wang P, König C,
Akino T, Sandlund J, Coma S, Italiano JE Jr, Mammoto A, Bielenberg
DR and Klagsbrun M: Netrin-1 promotes glioblastoma cell
invasiveness and angiogenesis by multiple pathways including
activation of RhoA, cathepsin B, and cAMP-response element-binding
protein. J Biol Chem. 288:2210–2222. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Withana NP, Blum G, Sameni M, Slaney C,
Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K, et
al: Cathepsin B inhibition limits bone metastasis in breast cancer.
Cancer Res. 72:1199–1209. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tummalapalli P, Spomar D, Gondi CS,
Olivero WC, Gujrati M, Dinh DH and Rao JS: RNAi-mediated abrogation
of cathepsin B and MMP-9 gene expression in a malignant meningioma
cell line leads to decreased tumor growth, invasion and
angiogenesis. Int J Oncol. 31:1039–1050. 2007.PubMed/NCBI
|
|
46
|
Gocheva V, Zeng W, Ke D, Klimstra D,
Reinheckel T, Peters C, Hanahan D and Joyce JA: Distinct roles for
cysteine cathepsin genes in multistage tumorigenesis. Genes Dev.
20:543–556. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Andl CD, McCowan KM, Allison GL and Rustgi
AK: Cathepsin B is the driving force of esophageal cell invasion in
a fibroblast-dependent manner. Neoplasia. 12:485–498. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Guo M, Mathieu PA, Linebaugh B, Sloane BF
and Reiners JJ Jr: Phorbol ester activation of a proteolytic
cascade capable of activating latent transforming growth
factor-betaL a process initiated by the exocytosis of cathepsin B.
J Biol Chem. 277:14829–14837. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Steffan JJ, Snider JL, Skalli O, Welbourne
T and Cardelli JA: Na+/H+ exchangers and RhoA
regulate acidic extracellular pH-induced lysosome trafficking in
prostate cancer cells. Traffic. 10:737–753. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bayrak R, Yenidünya S and Haltas H:
Cytokeratin 7 and cytokeratin 20 expression in colorectal
adenocarcinoma. Pathol Res Pract. 207:156–60. 2011. View Article : Google Scholar : PubMed/NCBI
|
